Multicenter Evaluation Sheds Further Light on Anti-HIV Activity of Entecavir (Baraclude) At the 2007 Conference on Retroviruses and Opportunistic Infections (CROI), researchers reported that entecavir (Baraclude), a nucleoside analog approved for the treatment of chronic hepatitis B virus (HBV)...
Entecavir (Baraclude) Multicenter Evaluation Sheds Further Light on Anti-HIV Activity of At the 2007 Conference on Retroviruses and Opportunistic Infections (CROI), researchers reported that entecavir (Baraclude), a nucleoside analog approved for the...
Entecavir Boosts Hepatitis B Response After Lamivudine Failure TORONTO, July 1 -- Patients who were lamivudine (Epivir) refractory saw improved hepatitis B suppression that lasted through almost two years of treatment with entecavir (Baraclude). The percentage of patients with fewer than 300 HBV...
NICE Issues Final Appraisal Determination (FAD) Which Recommends Baraclude(R) (Entecavir) as a Treatment Optio NICE (National Institute for Health and Clinical Excellence) has announced today, in its Final Appraisal Determination (FAD), that Baraclude(R) (entecavir) is recommended as an option for treatment of eligible patients with chronic hepatitis...
NICE Issues Final Appraisal Determination (FAD) Which Recommends Baraclude(R) (Entecavir) as a Treatment Optio NICE (National Institute for Health and Clinical Excellence) has announced today, in its Final Appraisal Determination (FAD), that Baraclude(R) (entecavir) is recommended as an option for treatment of eligible patients with chronic hepatitis...
NICE Issues Final Appraisal Determination (FAD) Which Recommends Baraclude(R) (Entecavir) as a Treatment Optio PMUXBRIDGE, England, June 25 /PRNewswire/ -- NICE (National Institute for Health and Clinical Excellence) has announced today, in its Final Appraisal Determination (FAD), that Baraclude(R) (entecavir) is recommended as an option for...
NICE backs Bristol-Myers drug for hepatitis B am LONDON (Reuters) - Bristol-Myers Squibb said on Wednesday its hepatitis B drug Baraclude had been recommended by the cost-effectiveness watchdog NICE, boosting a product seen as a growth driver for the U.S.company.
...
UK's NICE backs Bristol-Myers drug for hepatitis B LONDON, June 25 (Reuters) - Bristol-Myers Squibb Co (BMY.N: Quote, Profile, Research, Stock Buzz) said on Wednesday its hepatitis B drug Baraclude had been recommended by Britain's cost-effectiveness watchdog NICE, boosting a product...
UK's NICE Backs Baraclude for Hepatitis B _ UK's NICE Backs Baraclude for Hepatitis B.
UK's NICE Backs Baraclude for Hepatitis B _ UK's NICE Backs Baraclude for Hepatitis B.
Baraclude gets nod from NICE _ Baraclude gets nod from NICE.
BMS posts new data from E.A.R.L.Y. study Bristol-Myers Squibb Company posted new data from the E.A.R.L.Y.study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with Baraclude (entecavir) resulted in greater long-term viral load reduction...
Bristol-Myers Squibb Company today announced new data from the E.A.R.L.Y. study (ETV-079) , in which treatment of antiviral-nave adult chronic hepatitis B patients with BARACLUDE (entecavir) resulted in greater long-term viral load reduction than adefovir at 96 weeks -- consistent with earlier 12-week results (primary...
